FDA Classifies Setmelanotide Eligibility Gene Variant Detection System into Class II, Special Controls

Summary

The FDA is classifying the setmelanotide eligibility gene variant detection system into Class II, special controls, to ensure safety and effectiveness, and reduce regulatory burdens, thereby enhancing patients' access to innovative devices.